Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Akorn Faces Hurdles In Returning To Path Of Profitable Growth

Executive Summary

A new management team at Akorn is making progress on moving on from Fresenius Kabi’s ill-fated takeover bid; but putting manufacturing problems behind the US injectables and ophthalmics specialist is proving difficult.

You may also be interested in...



Akorn Extends Lenders Standstill With Aim To Sell Company

US generics company Akorn, which has been struggling since Germany’s Fresenius walked away from a $4.3bn merger three years ago, plans to put itself up for sale under an extended standstill agreement with lenders.

Akorn Receives Second Warning Letter In Six Months

Akorn Reports ‘Sustained’ Progress On FDA Issues

Beleaguered niche generic drugmaker Akorn has reported stronger-than-expected first-quarter earnings and says it is making progress on resolving FDA-related compliance problems.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB140142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel